Should Surveillance for Liver Cancer be Modified in Hepatitis C Patients After Treatment-related Cirrhosis Regression?

Roberta D'Ambrosio; Massimo Colombo


Liver International. 2016;36(6):783-790. 

In This Article


Cirrhosis regression has clearly been documented to occur and provide clinical benefits in hepatitis C patients achieving a SVR to interferon-based regimens, yet its prevalence is difficult to establish. In most cases, this is the consequence of the retrospective design of the studies done so far and of the diagnostic inaccuracy of both invasive and non-invasive tests for liver fibrosis that have been applied to heterogeneous patient populations. Evidence has also cumulated that a majority of patients with far advanced liver disease will not experience cirrhosis regression at all, and this is even more so in patients with cofactors of liver disease like alcohol abuse and type 2 diabetes. These same patients more exposed to risks of developing HCC likely represent a priority target population for surveillance.